In this study, four such patients had a much shorter time to distant metastatic relapse as compared to both patients with no detectable DTCs and importantly, patients with ERBB2-positive DTCs who were treated with Trastuzumab because their primary tumor was also ERBB2 positive. This evidence concerns the gene ERBB2 and neoplasm.